No title
The success of cancer immunotherapy depends on the priming of tumor-specific T and B lymphocytes. However, tumor cells often downregulate antigen presentation and mount an immunosuppressive tumor microenvironment (TME), which excludes immunogenic cells and hinders broad success of cancer immunotherapies, including immune checkpoint blockade (ICB). Type 1 conventional dendritic cells (cDC1s) are cr
